Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

<< Previous

Bullboard Posts

Next >>

Post by QualityTeston Dec 15, 2020 12:05pm

223 Views

Post# 32109211

Eli Lilly + Provision

Eli Lilly announced their acquisition of Provision today:
https://abcnews.go.com/Business/wireStory/lilly-lays-2021-expectations-gene-therapy-acquisition-74735666?cid=clicksource_4380645_2_heads_hero_live_headlines_hed
- "Lilly executives had indicated that they were looking to make smaller, so-called tuck-in acquisitions involving companies that specialize in gene therapy, said Dr. Vamil Divan, an analyst for Mizuho Securities USA."
I know someone who fits the bill for this! Heck, they can even give EL a hand with Jardiance (co-owned by Boehringer Ingelheim, an already-invested-in-RVX party).

<< Previous

Bullboard Posts

Next >>

Global Tungsten Market and Supply Security